Skip to main content

Table 3 Results of company network meta-analysis

From: Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Outcome Comparator Median HR vs. Nab-Pac + Gem (95% CrI)
Company base case Reduced network sensitivity analysis
OS Gem + Cap 0.970 (0.640–1.47) 1.10 (0.67–1.84)
FOLFIRINOX 0.77 (0.580–1.01) 0.77 (0.58–1.01)
PFS Gem + Cap 1.15 (1.00–1.70) 1.17 (0.75–1.86)
FOLFIRINOX 0.77 (0.58–1.02) 0.68 (0.51–0.91)
  1. CrI credible interval, FOLFIRINOX combination of oxaliplatin, irinotecan, leucovorin and fluorouracil, Gem + Cap gemcitabine in combination with capecitabine, HR hazard ratio, Nab-Pac + Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine, OS overall survival, PFS progression-free survival
Back to article page